Form 4 for GILD Gilead Sciences
Accepted 2024-12-16 00:00:00 ET · period of report 2023-12-13 · accession 0001127602-24-029490 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-16 | 2023-12-13+ | GILD | Patterson Sandra | SVP, Controllership | M - OptEx | — | +455 | 37.5K | +1% | — |
| DM | 2024-12-16 | 2023-12-13+ | GILD | Patterson Sandra | SVP, Controllership | F - Tax | $86.12 | -455 | 37.1K | -1% | -$39.2K |
| DM | 2024-12-16 | 2023-12-13+ | GILD | Patterson Sandra | SVP, Controllership | M - OptEx | — | -455 | 12.0K | -4% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-13 | M | A | 117 | — | 37,376 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2023-12-13 | F | D | 298 | $83.09 | 37,235 | D | — | — | |
| 3 | Common | Common Stock | 2024-12-13 | F | D | 157 | $91.86 | 37,078 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-13 | M | A | 181 | — | 37,259 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 5 | Common | Common Stock | 2024-12-13 | M | A | 157 | — | 37,533 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 6 | Derivative | Restricted Stock Unit | 2024-12-13 | M | D | 157 | — | 11,827 | D | — · — to — | 157 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F4) The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2023-12-13 | M | D | 181 | — | 12,101 | D | — · — to — | 181 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. |
| 8 | Derivative | Restricted Stock Unit | 2023-12-13 | M | D | 117 | — | 11,984 | D | — · — to — | 117 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F4) The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |